2016
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Abstract: Summary Using transgenic mouse models, cell line-based functional studies and clinical specimens, we show that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive breast cancer. This is overcome using CDK4/6 inhibitors. Inhibition of CDK4/6 not only suppresses Rb phosphorylation, but also reduces TSC2 phosphorylation and thus partially attenuates mTORC1 activity. This relieves feedback inhibition of upstream EGFR-family kinases, re-sensitizing tumors to EGFR/HER2 blockade. Consequently, dua…
Search citation statements
Paper Sections
Select...
364
85
61
20
Citation Types
25
459
2
4
Year Published
2016
2026
Publication Types
Select...
385
47
39
19
Relationship
27
463
Authors
Journals
Cited by 479 publications
(491 citation statements)
References 30 publications
25
459
2
4
“…The changes in gene expression were confirmed at the protein level for a number of E2F dependent genes (Figure 2E). Interestingly, despite reports that CDK4/6 inhibition leads to increased phosphorylation of AKT through RB suppression of mTORC2 activation (24, 25), we found no evidence of increased AKT phosphorylation or altered mTOR signalling by palbociclib in our experiments (Figure 2C).…”
Section: Resultscontrasting
confidence: 95%
“…The changes in gene expression were confirmed at the protein level for a number of E2F dependent genes (Figure 2E). Interestingly, despite reports that CDK4/6 inhibition leads to increased phosphorylation of AKT through RB suppression of mTORC2 activation (24, 25), we found no evidence of increased AKT phosphorylation or altered mTOR signalling by palbociclib in our experiments (Figure 2C).…”
Section: Resultscontrasting
confidence: 95%
“…While our data indicated that palbociclib may affect multiple pathways including the PI3K/AKT/mTOR signaling pathway (Fig EV3D), the PI3K/AKT/mTOR pathway inhibition was weak and evident only at higher drug concentrations (Fig EV3E–G). These findings are consistent with previous observations that CDK4/6 inhibition can partially attenuate mTORC1 activity (Goel et al , ).…”
Section: Resultssupporting
confidence: 94%
“…3B ). These observations are in agreement with the already known “senescence-like phenotype” induced by CDK4/6 inhibitors ( 19, 27, 28 ). As for classical senescence, we found that cells treated with palbociclib for 72 hours showed an activation of the SA β-gal ( Fig.…”
Section: Resultssupporting
confidence: 92%
“…A clear senescence-like phenotype was observed at the end of the 72 h treatment in BT474 and MCF7 (as example of HER2+ and HER2 low cells) (Fig 3a ); indeed cells showed altered morphology, flattening and increased cell area (Fig 3b). These observations are in agreement with the already known "senescence-like phenotype" induced by CDK4/6 inhibitors 19,27,28 As for classical senescence, we found that cells treated with Palbociclib for 72 h showed an activation of the Senescence Associated galactosidase (SA -gal) (Figure 3a). However, after Palbociclib removal (3 days WO) cells reverted to the original appearance and the activity of SA -gal decreased.…”
Section: Resultssupporting
confidence: 92%
